Cai Yunxiang, Zhong Huaping, Huang Zhenhe
Department of Otolaryngology Head and Neck Surgery, Ganzhou People's Hospital Ganzhou, Jiangxi, China.
Department of Cardiovascular Medicine, The First Affiliated Hospital of Gannan Medical College Ganzhou, Jiangxi, China.
Am J Transl Res. 2023 Jul 15;15(7):4439-4453. eCollection 2023.
Nasopharyngeal carcinoma is a prevalent malignant tumor in clinical practice, with the highest incidence rate among otorhinolaryngological malignant tumors.
This study aims to comprehensively evaluate the clinical efficacy and safety of traditional Chinese medicine compound (CMC) combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (LA-NPC).
Relevant essays published before November 20, 2021, were retrieved from China National Knowledge Internet (CNKI), China Science and Technology Journal Database (CQVIP), Wanfang database, PubMed, and Web of Science databases. Randomized controlled trials regarding the clinical efficacy of CMC combined with concurrent radiotherapy and chemotherapy in the treatment of LA-NPC were included.
A total of 15 publications involving 1324 patients were included in this study, including 665 in the experimental group and 659 in the control group. Meta-analyses revealed that compared with radiotherapy or chemotherapy only, CMC combined with concurrent radiotherapy and chemotherapy for LA-NPC significantly improved the efficacy [risk ratio (RR)=1.15, 95% confidence interval (95% CI) (1.09, 1.20), <0.00001], the quality of life [RR=1.35, 95% CI (1.13, 1.62), =0.0009], immune function indices CD4+ levels [RR=6.2, 95% CI (3.64, 8.76), <0.00001], CD4+/CD8+ [RR=0.33, 95% CI (0.14, 0.53), =0.0009], and alleviated the decrease in white blood cell counts [RR=0.67, 95% CI (0.52, 0.86), =0.002].
CMC combined with concurrent radiotherapy and chemotherapy for the treatment of LA-NPC can significantly improve the efficacy and reduce severe adverse reactions caused by conventional radiotherapy and chemotherapy. However, due to limitations in the quantity and quality of the included studies, more high-quality, multi-center, and large sample-size studies are needed to provide high-level and high-quality medical evidence for systematic evaluation.
鼻咽癌是临床常见的恶性肿瘤,在耳鼻咽喉科恶性肿瘤中发病率最高。
本研究旨在综合评价中药复方(CMC)联合同期放化疗治疗局部晚期鼻咽癌(LA-NPC)的临床疗效和安全性。
检索中国知网(CNKI)、中国科技期刊数据库(CQVIP)、万方数据库、PubMed及Web of Science数据库中2021年11月20日前发表的相关文献。纳入关于CMC联合同期放化疗治疗LA-NPC临床疗效的随机对照试验。
本研究共纳入15篇文献,涉及1324例患者,其中试验组665例,对照组659例。Meta分析显示,与单纯放疗或化疗相比,CMC联合同期放化疗治疗LA-NPC可显著提高疗效[风险比(RR)=1.15,95%置信区间(95%CI)(1.09,1.20),<0.00001]、生活质量[RR=1.35,95%CI(1.13,1.62),=0.0009]、免疫功能指标CD4+水平[RR=6.2,95%CI(3.64,8.76),<0.00001]、CD4+/CD8+[RR=0.33,95%CI(0.14,0.53),=0.0009],并减轻白细胞计数下降[RR=0.67,95%CI(0.52,0.86),=0.002]。
CMC联合同期放化疗治疗LA-NPC可显著提高疗效,减少传统放化疗引起的严重不良反应。然而,由于纳入研究的数量和质量有限,需要更多高质量、多中心、大样本量的研究,为系统评价提供高水平、高质量的医学证据。